ACADIA Pharmaceuticals Inc. (ACAD)
USD 14.86
(1.92%)
USD 14.86
(1.92%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 754.08 Million USD | 3.21% |
| 2022 | 730.66 Million USD | 14.99% |
| 2021 | 635.44 Million USD | -10.22% |
| 2020 | 707.79 Million USD | 25.05% |
| 2019 | 566.02 Million USD | 24.97% |
| 2018 | 452.92 Million USD | 12.04% |
| 2017 | 404.25 Million USD | 41.48% |
| 2016 | 285.74 Million USD | 73.52% |
| 2015 | 164.67 Million USD | 76.4% |
| 2014 | 93.35 Million USD | 136.68% |
| 2013 | 39.44 Million USD | 52.92% |
| 2012 | 25.79 Million USD | 3.51% |
| 2011 | 24.91 Million USD | -7.85% |
| 2010 | 27.04 Million USD | -47.86% |
| 2009 | 51.86 Million USD | -24.36% |
| 2008 | 68.56 Million USD | -2.34% |
| 2007 | 70.2 Million USD | 22.77% |
| 2006 | 57.18 Million USD | 22.29% |
| 2005 | 46.76 Million USD | 52.32% |
| 2004 | 30.69 Million USD | 45.37% |
| 2003 | 21.11 Million USD | 11.73% |
| 2002 | 18.9 Million USD | -0.48% |
| 2001 | 18.99 Million USD | 21.9% |
| 2000 | 15.58 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 167.67 Million USD | -5.91% |
| 2024 Q2 | 193.29 Million USD | 15.28% |
| 2023 Q1 | 170.37 Million USD | -5.42% |
| 2023 Q2 | 154.73 Million USD | -9.18% |
| 2023 FY | 754.08 Million USD | 3.21% |
| 2023 Q4 | 178.2 Million USD | -30.07% |
| 2023 Q3 | 254.85 Million USD | 64.7% |
| 2022 Q1 | 225.53 Million USD | 30.48% |
| 2022 FY | 730.66 Million USD | 14.99% |
| 2022 Q4 | 180.14 Million USD | 12.98% |
| 2022 Q3 | 159.44 Million USD | -3.69% |
| 2022 Q2 | 165.54 Million USD | -26.6% |
| 2021 Q3 | 140.23 Million USD | -8.78% |
| 2021 Q4 | 172.85 Million USD | 23.26% |
| 2021 FY | 635.44 Million USD | -10.22% |
| 2021 Q1 | 168.63 Million USD | -7.78% |
| 2021 Q2 | 153.72 Million USD | -8.84% |
| 2020 Q4 | 182.86 Million USD | -9.33% |
| 2020 FY | 707.79 Million USD | 25.05% |
| 2020 Q1 | 174.6 Million USD | 16.88% |
| 2020 Q2 | 148.63 Million USD | -14.87% |
| 2020 Q3 | 201.67 Million USD | 35.68% |
| 2019 Q2 | 135.3 Million USD | -7.34% |
| 2019 Q4 | 149.39 Million USD | 10.4% |
| 2019 Q1 | 146.01 Million USD | 19.24% |
| 2019 Q3 | 135.31 Million USD | 0.01% |
| 2019 FY | 566.02 Million USD | 24.97% |
| 2018 Q2 | 116.06 Million USD | 15.83% |
| 2018 FY | 452.92 Million USD | 12.04% |
| 2018 Q4 | 122.45 Million USD | 7.23% |
| 2018 Q3 | 114.2 Million USD | -1.61% |
| 2018 Q1 | 100.2 Million USD | -8.8% |
| 2017 Q3 | 98.67 Million USD | 3.11% |
| 2017 FY | 404.25 Million USD | 41.48% |
| 2017 Q1 | 101.15 Million USD | 15.1% |
| 2017 Q2 | 95.7 Million USD | -5.39% |
| 2017 Q4 | 109.86 Million USD | 11.34% |
| 2016 Q1 | 50.26 Million USD | 10.28% |
| 2016 FY | 285.74 Million USD | 73.52% |
| 2016 Q3 | 76.34 Million USD | 7.16% |
| 2016 Q4 | 87.88 Million USD | 15.11% |
| 2016 Q2 | 71.24 Million USD | 41.74% |
| 2015 FY | 164.67 Million USD | 76.4% |
| 2015 Q4 | 45.58 Million USD | 16.77% |
| 2015 Q3 | 39.03 Million USD | -1.17% |
| 2015 Q2 | 39.49 Million USD | -2.61% |
| 2015 Q1 | 40.55 Million USD | 41.79% |
| 2014 Q3 | 25 Million USD | 14.98% |
| 2014 FY | 93.35 Million USD | 136.68% |
| 2014 Q1 | 17.98 Million USD | 47.43% |
| 2014 Q4 | 28.6 Million USD | 14.37% |
| 2014 Q2 | 21.75 Million USD | 20.92% |
| 2013 FY | 39.44 Million USD | 52.92% |
| 2013 Q1 | 6.58 Million USD | -8.58% |
| 2013 Q2 | 9.6 Million USD | 46.0% |
| 2013 Q3 | 11.05 Million USD | 15.02% |
| 2013 Q4 | 12.2 Million USD | 10.41% |
| 2012 FY | 25.79 Million USD | 3.51% |
| 2012 Q1 | 6.68 Million USD | 13.2% |
| 2012 Q2 | 6.02 Million USD | -9.77% |
| 2012 Q3 | 5.88 Million USD | -2.37% |
| 2012 Q4 | 7.19 Million USD | 22.33% |
| 2011 FY | 24.91 Million USD | -7.85% |
| 2011 Q2 | 7.04 Million USD | 11.88% |
| 2011 Q3 | 5.67 Million USD | -19.41% |
| 2011 Q4 | 5.9 Million USD | 3.96% |
| 2011 Q1 | 6.29 Million USD | 0.33% |
| 2010 Q2 | 6.59 Million USD | -13.58% |
| 2010 Q1 | 7.62 Million USD | -27.17% |
| 2010 Q3 | 6.54 Million USD | -0.76% |
| 2010 FY | 27.04 Million USD | -47.86% |
| 2010 Q4 | 6.27 Million USD | -4.1% |
| 2009 Q2 | 14.64 Million USD | -5.8% |
| 2009 Q4 | 10.47 Million USD | -6.55% |
| 2009 Q3 | 11.2 Million USD | -23.44% |
| 2009 Q1 | 15.54 Million USD | 6.92% |
| 2009 FY | 51.86 Million USD | -24.36% |
| 2008 Q4 | 14.53 Million USD | -11.21% |
| 2008 FY | 68.56 Million USD | -2.34% |
| 2008 Q3 | 16.37 Million USD | -14.82% |
| 2008 Q1 | 19.24 Million USD | -5.13% |
| 2008 Q2 | 19.22 Million USD | -0.14% |
| 2007 Q2 | 14.65 Million USD | -4.9% |
| 2007 Q1 | 15.41 Million USD | 0.59% |
| 2007 FY | 70.2 Million USD | 22.77% |
| 2007 Q4 | 20.28 Million USD | 2.21% |
| 2007 Q3 | 19.85 Million USD | 35.42% |
| 2006 Q4 | 15.32 Million USD | 5.81% |
| 2006 FY | 57.18 Million USD | 22.29% |
| 2006 Q1 | 12.63 Million USD | -3.85% |
| 2006 Q3 | 14.48 Million USD | -1.78% |
| 2006 Q2 | 14.74 Million USD | 16.68% |
| 2005 Q2 | 9 Million USD | 10.87% |
| 2005 Q1 | 8.12 Million USD | -4.84% |
| 2005 FY | 46.76 Million USD | 52.32% |
| 2005 Q4 | 13.14 Million USD | -20.28% |
| 2005 Q3 | 16.48 Million USD | 83.01% |
| 2004 Q1 | 7.35 Million USD | 134.83% |
| 2004 Q4 | 8.53 Million USD | 8.03% |
| 2004 Q3 | 7.9 Million USD | 14.53% |
| 2004 Q2 | 6.9 Million USD | -6.18% |
| 2004 FY | 30.69 Million USD | 45.37% |
| 2003 Q3 | - USD | -100.0% |
| 2003 Q4 | -21.11 Million USD | 0.0% |
| 2003 FY | 21.11 Million USD | 11.73% |
| 2003 Q1 | 4.13 Million USD | 0.0% |
| 2003 Q2 | 4.32 Million USD | 4.67% |
| 2002 FY | 18.9 Million USD | -0.48% |
| 2001 FY | 18.99 Million USD | 21.9% |
| 2000 FY | 15.58 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agenus Inc. | 78.18 Million USD | -864.513% |
| Immix Biopharma, Inc. | 16.14 Million USD | -4571.828% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -345.474% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -400.933% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -98.185% |
| MiMedx Group, Inc. | 229.72 Million USD | -228.253% |
| Novavax, Inc. | 779.12 Million USD | 3.214% |
| Seer, Inc. | 110.49 Million USD | -582.492% |
| Acelyrin, Inc. | 422.06 Million USD | -78.666% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -347.698% |
| IO Biotech, Inc. | 91.44 Million USD | -724.65% |
| Ardelyx, Inc. | 169.93 Million USD | -343.744% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -371.931% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -5321.312% |
| Fortress Biotech, Inc. | 200.19 Million USD | -276.675% |
| Fortress Biotech, Inc. | 200.19 Million USD | -276.675% |
| Geron Corporation | 70.44 Million USD | -970.52% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -69.177% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2202.831% |
| Incyte Corporation | 1.19 Billion USD | 36.658% |
| Innoviva, Inc. | 132.15 Million USD | -470.611% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -8823.027% |
| ChromaDex Corporation | 56.37 Million USD | -1237.528% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -794.282% |
| MEI Pharma, Inc. | 34.78 Million USD | -2067.845% |
| NextCure, Inc. | 67.63 Million USD | -1014.9% |
| Onconetix, Inc. | 34.9 Million USD | -2060.242% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -5816.248% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1819.51% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -377.831% |
| Vaxcyte, Inc. | 468.04 Million USD | -61.115% |
| Precigen, Inc. | 84.18 Million USD | -795.79% |
| Pharming Group N.V. | 225.49 Million USD | -234.419% |
| ContextLogic Inc. | 387 Million USD | -94.854% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -3883.755% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -817.423% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -478.894% |
| AlloVir, Inc. | 180.93 Million USD | -316.776% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3002.387% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -369.718% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -5848240.313% |
| Summit Therapeutics Inc. | 87.68 Million USD | -759.983% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -227.929% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1934.548% |
| Senti Biosciences, Inc. | 94.7 Million USD | -696.246% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -338.671% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -2458.909% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -470.52% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -27305.477% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1319.417% |
| Chimerix, Inc. | 93.38 Million USD | -707.467% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1651.843% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4219.671% |
| CRISPR Therapeutics AG | 463.49 Million USD | -62.696% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -315.93% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -349.323% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -939.171% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -679.738% |
| Precision BioSciences, Inc. | 92.46 Million USD | -715.553% |
| Dyadic International, Inc. | 9.15 Million USD | -8138.939% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1559.335% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -3288.689% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -274.952% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 58.108% |
| Aptorum Group Limited | 10.56 Thousand USD | -7136801.382% |
| Bicycle Therapeutics plc | 216.92 Million USD | -247.63% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -19029.27% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2205.013% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -11101.593% |
| GT Biopharma, Inc. | 13.57 Million USD | -5454.545% |
| Alkermes plc | 996.24 Million USD | 24.307% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -968.2% |
| Jaguar Health, Inc. | 42.01 Million USD | -1694.799% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2112.366% |
| AbCellera Biologics Inc. | 275.23 Million USD | -173.982% |
| PureTech Health plc | 144.59 Million USD | -421.508% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -3783.33% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -229.756% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1891.299% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -790.133% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3002.387% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -706.698% |
| AnaptysBio, Inc. | 181.56 Million USD | -315.318% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2128.12% |
| ESSA Pharma Inc. | 32.13 Million USD | -2246.681% |
| Molecular Templates, Inc. | 63.09 Million USD | -1095.234% |
| Scopus BioPharma Inc. | 11.71 Million USD | -6336.986% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -86.857% |
| Vaxxinity, Inc. | 56.05 Million USD | -1245.355% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1387.553% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -2343.647% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -830.257% |
| Structure Therapeutics Inc. | 102.77 Million USD | -633.724% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1228.573% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -510.333% |
| ImmuCell Corporation | 9.61 Million USD | -7740.872% |
| Lantern Pharma Inc. | 17.87 Million USD | -4118.051% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -2440.546% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -2447.068% |
| Opthea Limited | 191.96 Million USD | -292.819% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -207.591% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -2350.635% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -196.832% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -243.031% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -190.676% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1294.388% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -7488.166% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -190.414% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1340.303% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -5132.931% |
| Soligenix, Inc. | 7.79 Million USD | -9573.646% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1244.875% |
| Kura Oncology, Inc. | 165.8 Million USD | -354.805% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -558.549% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -8964.611% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -30286.571% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -600.185% |
| Autolus Therapeutics plc | 196.72 Million USD | -283.317% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -790.753% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -547.545% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -3790.445% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -134.364% |
| GRI Bio, Inc. | 11.33 Million USD | -6555.649% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -10587.599% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -474.791% |
| IGM Biosciences, Inc. | 265.59 Million USD | -183.927% |
| INmune Bio, Inc. | 29.89 Million USD | -2422.361% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -337.014% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1770.514% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4619.119% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -4690.41% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1114.347% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -601.331% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -173.523% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -150.152% |
| Verastem, Inc. | 92.08 Million USD | -718.91% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -4103.606% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -306.022% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -521.122% |
| Histogen Inc. | 14.27 Million USD | -5183.667% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -4598.893% |
| Surrozen, Inc. | 18.55 Million USD | -3965.148% |
| Organovo Holdings, Inc. | 14.91 Million USD | -4955.883% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -14714.343% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1163.692% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -2840.246% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1504.231% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -9779.477% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -323.32% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1456.485% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -207.785% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -4807.307% |
| Apollomics, Inc. | 54.14 Million USD | -1292.843% |
| Amarin Corporation plc | 272.35 Million USD | -176.874% |
| Mesoblast Limited | 5.9 Million USD | -12676.771% |
| Turnstone Biologics Corp. | 78.33 Million USD | -862.604% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -208.897% |
| Synaptogenix, Inc. | 8.31 Million USD | -8970.222% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -5069.923% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -197.991% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2162.476% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -8438.84% |
| Exelixis, Inc. | 1.58 Billion USD | 52.477% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1870.846% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -224.967% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 11.824% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6286.728% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -9276.944% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -2414.203% |
| Gritstone bio, Inc. | 148.37 Million USD | -408.233% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -995.083% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -4509.26% |
| Avid Bioservices, Inc. | 25.99 Million USD | -2800.773% |
| Insmed Incorporated | 949.26 Million USD | 20.561% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -4706.215% |
| MediWound Ltd. | 18.86 Million USD | -3896.635% |
| OmniAb, Inc. | 83.89 Million USD | -798.844% |
| Alector, Inc. | 248.8 Million USD | -203.086% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -221.835% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1343.197% |
| Zai Lab Limited | 547.47 Million USD | -37.738% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -89.158% |
| Aura Biosciences, Inc. | 84.99 Million USD | -787.253% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -205.127% |
| Immunic, Inc. | 99.22 Million USD | -659.99% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -374.232% |
| Veracyte, Inc. | 357.93 Million USD | -110.678% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 91.636% |
| FibroGen, Inc. | 398.11 Million USD | -89.415% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5206.721% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -10847.892% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -10482.562% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 76.837% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -2814.563% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -138.225% |
| TG Therapeutics, Inc. | 198.47 Million USD | -279.94% |
| Galecto, Inc. | 35.62 Million USD | -2016.611% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -1753.29% |
| Fortrea Holdings Inc. | 457.3 Million USD | -64.899% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1289.301% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -2511.278% |
| XBiotech Inc. | 37.51 Million USD | -1910.357% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -995.083% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -3551.92% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -430.818% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -661.125% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -581.098% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 21.306% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -2514.266% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -75.108% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -3280.287% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -580.171% |
| NexImmune, Inc. | 28.16 Million USD | -2577.145% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -13533.92% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -4114.529% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 73.215% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -2861.958% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -493.478% |
| Ainos, Inc. | 12.95 Million USD | -5721.853% |
| Pluri Inc. | 22.48 Million USD | -3254.471% |
| Prothena Corporation plc | 282.4 Million USD | -167.022% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -277.001% |
| Celularity Inc. | 215.05 Million USD | -250.643% |
| Rallybio Corporation | 78.93 Million USD | -855.36% |
| Cue Biopharma, Inc. | 19.54 Million USD | -3758.791% |
| MeiraGTx Holdings plc | 151.07 Million USD | -399.136% |
| Omeros Corporation | 94.75 Million USD | -695.86% |
| Humacyte, Inc. | 23.49 Million USD | -3109.282% |
| Immunocore Holdings plc | 308.04 Million USD | -144.801% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -22144.395% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -768.111% |
| Blueprint Medicines Corporation | 722.86 Million USD | -4.32% |
| CalciMedica, Inc. | 21.81 Million USD | -3356.41% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -910.025% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -340.226% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -155.674% |
| Pulmatrix, Inc. | 22.03 Million USD | -3321.749% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2081.012% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -748.564% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -36.717% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -939.386% |
| Cytokinetics, Incorporated | 173.61 Million USD | -334.351% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2090.897% |
| Nutriband Inc. | 5.73 Million USD | -13051.045% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1629.037% |
| Vor Biopharma Inc. | 126.03 Million USD | -498.309% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 36.588% |
| Evogene Ltd. | 27.79 Million USD | -2613.512% |
| ProKidney Corp. | 151.52 Million USD | -397.674% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -916.63% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -9703.189% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -22.77% |
| CorMedix Inc. | 48.95 Million USD | -1440.276% |
| BioLineRx Ltd. | 50.8 Million USD | -1384.361% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -400.388% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1880.681% |
| Atai Life Sciences N.V. | 125.78 Million USD | -499.503% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -823.679% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -826.292% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -198.586% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2203.253% |
| MediciNova, Inc. | 10.9 Million USD | -6818.043% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -485.379% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10287.527% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12421.809% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -58.301% |
| Biomea Fusion, Inc. | 126.13 Million USD | -497.84% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 42.517% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2003.914% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -294.625% |
| Absci Corporation | 73.66 Million USD | -923.654% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2633.975% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -464.477% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -211.397% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -187.766% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -262.551% |
| Allakos Inc. | 196.05 Million USD | -284.627% |
| Imunon, Inc. | 20.31 Million USD | -3612.798% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -564.574% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -104.574% |
| BioAtla, Inc. | 129.68 Million USD | -481.465% |
| NLS Pharmaceutics AG | 11.8 Million USD | -6286.728% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -4659.736% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -788.015% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -1705.846% |
| XOMA Corporation | 46.46 Million USD | -1522.98% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -578.311% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -429.32% |
| aTyr Pharma, Inc. | 12.97 Million USD | -5710.039% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -627.488% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -336.215% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -195.994% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1915.839% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -9068.414% |
| Akari Therapeutics, Plc | 16.8 Million USD | -4386.999% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -33061.607% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -151.934% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11106.944% |
| UroGen Pharma Ltd. | 138.88 Million USD | -442.945% |
| Sutro Biopharma, Inc. | 243 Million USD | -210.312% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -10265.968% |
| Orgenesis Inc. | 45.75 Million USD | -1548.021% |
| Entera Bio Ltd. | 8.86 Million USD | -8411.117% |
| GH Research PLC | 41.22 Million USD | -1729.327% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -2833.27% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -807.956% |
| Xencor, Inc. | 306.97 Million USD | -145.649% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -15184.662% |
| Replimune Group, Inc. | 234.77 Million USD | -221.197% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -3580.279% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -293.17% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -11106.944% |
| Portage Biotech Inc. | 18.19 Million USD | -4043.552% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -10287.527% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -618.443% |
| OncoCyte Corporation | 25.63 Million USD | -2841.393% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -12270.958% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -6481.836% |
| Purple Biotech Ltd. | -22.46 Million USD | 3456.412% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -4475.758% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1056.962% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -8821.194% |
| HilleVax, Inc. | 133.34 Million USD | -465.514% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -7231.891% |
| Tharimmune, Inc. | 9.45 Million USD | -7875.33% |
| Genprex, Inc. | 31.06 Million USD | -2327.789% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -302.123% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2303.305% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -98473.203% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -13744.248% |
| OKYO Pharma Limited | 8243.57 USD | -9147453.79% |
| Savara Inc. | 15.74 Million USD | -4689.362% |
| Curis, Inc. | 58.35 Million USD | -1192.237% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2143.673% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -14707.791% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -10007.023% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -2690.634% |
| BeiGene, Ltd. | 3.28 Billion USD | 77.056% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -3681.903% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -51.19% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -390.775% |
| Erasca, Inc. | 141.52 Million USD | -432.828% |
| bluebird bio, Inc. | 240.23 Million USD | -213.899% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -16557.595% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 56.818% |
| DBV Technologies S.A. | 92.16 Million USD | -718.235% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -16557.595% |
| Moderna, Inc. | 6.39 Billion USD | 88.206% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1669.779% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -5149.095% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1030.545% |
| Travere Therapeutics, Inc. | 472 Million USD | -59.763% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -426.188% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1114.66% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1636.963% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -262.314% |
| MacroGenics, Inc. | 217.21 Million USD | -247.161% |
| RenovoRx, Inc. | 11.39 Million USD | -6517.102% |
| Adicet Bio, Inc. | 152.03 Million USD | -395.985% |
| Prime Medicine, Inc. | 186.63 Million USD | -304.034% |
| Aditxt, Inc. | 25.95 Million USD | -2805.83% |
| Adagene Inc. | 41.83 Million USD | -1702.679% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10215.662% |
| Quantum-Si incorporated | 111.65 Million USD | -575.346% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -338.804% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -5072.843% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2005.089% |
| SciSparc Ltd. | 9.01 Million USD | -8268.494% |
| Vericel Corporation | 142.04 Million USD | -430.896% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8611.035% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -3166.05% |
| Generation Bio Co. | 144.46 Million USD | -421.977% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -808.208% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -772.178% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -155.0% |
| Invivyd, Inc. | 205.75 Million USD | -266.497% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -945.032% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -7940.568% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -902.053% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -7230.466% |
| 2seventy bio, Inc. | 289.88 Million USD | -160.131% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1032.498% |
| Clene Inc. | 41.07 Million USD | -1735.963% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -5787.662% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1276.168% |
| GeoVax Labs, Inc. | 6.02 Million USD | -12421.809% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -114.199% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1952.936% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2135.783% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -627.165% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2213.925% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -342.855% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 1.776% |
| Evaxion Biotech A/S | 22.27 Million USD | -3286.102% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -456.34% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -221.048% |
| Trevena, Inc. | 38.41 Million USD | -1863.098% |
| Surrozen, Inc. | 18.55 Million USD | -3965.148% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -843.255% |
| Cingulate Inc. | 22.75 Million USD | -3213.321% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 10165.203% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1588.237% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -9058.251% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -635.277% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1114.816% |
| Clearmind Medicine Inc. | 8.74 Million USD | -8526.642% |
| Kronos Bio, Inc. | 128.11 Million USD | -488.586% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -796.951% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -25610.496% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -647.9% |
| Statera Biopharma, Inc. | 28.82 Million USD | -2515.671% |
| ImmunityBio, Inc. | 362.87 Million USD | -107.81% |
| Korro Bio, Inc. | 84.53 Million USD | -792.049% |
| Kineta, Inc. | 21.15 Million USD | -3464.403% |
| BioVie Inc. | 31.95 Million USD | -2260.188% |
| Codexis, Inc. | 66.51 Million USD | -1033.656% |
| Celularity Inc. | 215.05 Million USD | -250.643% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -232.752% |
| Celcuity Inc. | 66.23 Million USD | -1038.58% |
| Virax Biolabs Group Limited | 6.54 Million USD | -11417.913% |
| Cibus, Inc. | 320.3 Million USD | -135.427% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1653.686% |
| IN8bio, Inc. | 30.33 Million USD | -2385.694% |
| Kodiak Sciences Inc. | 277.32 Million USD | -171.918% |
| Annexon, Inc. | 143.72 Million USD | -424.679% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -491.017% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -3191.654% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -117725.781% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 3.271% |
| Eyenovia, Inc. | 25.4 Million USD | -2868.085% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -437.423% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13457.803% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -852.934% |
| Arcellx, Inc. | 200.19 Million USD | -276.668% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1542.887% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -248.45% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -7473.416% |
| Moolec Science SA | 52.75 Million USD | -1329.529% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1133.415% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1520.294% |
| Royalty Pharma plc | 862.4 Million USD | 12.56% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -701.604% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -7984.218% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -3232.452% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -262.869% |
| Humacyte, Inc. | 23.49 Million USD | -3109.282% |
| 89bio, Inc. | 151.2 Million USD | -398.72% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -841.054% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -5086.279% |
| Genelux Corporation | 24.33 Million USD | -2998.767% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2122.931% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -336.218% |
| Notable Labs, Ltd. | 14.77 Million USD | -5005.518% |
| Liquidia Corporation | 87.98 Million USD | -757.071% |
| Mustang Bio, Inc. | 48.5 Million USD | -1454.782% |
| Immunovant, Inc. | 282.7 Million USD | -166.735% |
| Quantum-Si incorporated | 111.65 Million USD | -575.346% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -3244.948% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -3445.799% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -639.212% |
| Acasti Pharma Inc. | 11.3 Million USD | -6572.728% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -3189.916% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -4619.119% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1520.225% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -66363.802% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -4646.853% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -2486.291% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -1722.166% |
| PepGen Inc. | 84.76 Million USD | -789.608% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -2444.919% |
| United Therapeutics Corporation | 885.1 Million USD | 14.802% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -3193.379% |
| Solid Biosciences Inc. | 104.31 Million USD | -622.892% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2204.271% |
| Immuneering Corporation | 58.41 Million USD | -1190.957% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -14714.343% |
| Silo Pharma, Inc. | 3.92 Million USD | -19127.758% |
| Belite Bio, Inc | 31.66 Million USD | -2281.221% |
| XOMA Corporation | 46.46 Million USD | -1522.98% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1016.336% |
| Bionomics Limited | 17.89 Billion USD | 95.785% |
| Apogee Therapeutics, Inc. | 93 Million USD | -710.818% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2213.467% |
| uniQure N.V. | 285.08 Million USD | -164.511% |
| Cassava Sciences, Inc. | 105.95 Million USD | -611.69% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -10215.662% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -288.289% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2221.905% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -8975.788% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -2465.351% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -13457.803% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -5206.721% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -8383.35% |
| Altimmune, Inc. | 30.55 Million USD | -2367.879% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -76.332% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2213.467% |
| Compugen Ltd. | 43.97 Million USD | -1614.96% |
| Peak Bio, Inc. | 1249.13 USD | -60368716.696% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -917.384% |
| Benitec Biopharma Inc. | 22.38 Million USD | -3269.158% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -210.082% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -2541.926% |
| Zura Bio Limited | 62.63 Million USD | -1103.878% |
| PolyPid Ltd. | 21.04 Million USD | -3483.203% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -4533.11% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -2541.926% |
| Instil Bio, Inc. | 85.78 Million USD | -779.041% |
| argenx SE | 1.53 Billion USD | 50.827% |
| Immunome, Inc. | 122.82 Million USD | -513.976% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1455.68% |
| Verona Pharma plc | 67.15 Million USD | -1022.964% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -2813.212% |
| Shattuck Labs, Inc. | 93.61 Million USD | -705.526% |
| CervoMed Inc. | 14.95 Million USD | -4941.428% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -966.553% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -8725.901% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1378.598% |
| Moolec Science SA | 52.75 Million USD | -1329.529% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -4484.538% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -468.884% |
| Design Therapeutics, Inc. | 78.19 Million USD | -864.426% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -766.356% |
| NeurAxis, Inc. | 8.82 Million USD | -8448.554% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -5891.935% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1850.304% |
| Achilles Therapeutics plc | 75.25 Million USD | -902.04% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -2813.212% |
| 180 Life Sciences Corp. | 13.47 Million USD | -5495.14% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -2745.342% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -25610.496% |
| Nutriband Inc. | 5.73 Million USD | -13051.045% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -580.705% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1254.976% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1382.114% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1040.842% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1293.278% |
| Palisade Bio, Inc. | 13.32 Million USD | -5561.299% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1560.651% |
| Beam Therapeutics Inc. | 554.19 Million USD | -36.069% |
| Neurogene Inc. | 55.58 Million USD | -1256.683% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -203.468% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1457.094% |
| Sesen Bio, Inc. | 78.38 Million USD | -862.076% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -802.782% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -5891.032% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -67.205% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -757.987% |
| Athira Pharma, Inc. | 125.46 Million USD | -501.027% |
| Vaccinex, Inc. | 23.45 Million USD | -3115.029% |
| HCW Biologics Inc. | 21.02 Million USD | -3486.181% |
| XOMA Corporation | 46.46 Million USD | -1522.98% |
| Nektar Therapeutics | 190.9 Million USD | -295.01% |
| Arvinas, Inc. | 480 Million USD | -57.101% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -33061.607% |
| Merus N.V. | 200.49 Million USD | -276.113% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -629.607% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2078.177% |
| Rezolute, Inc. | 70.38 Million USD | -971.341% |
| Clene Inc. | 41.07 Million USD | -1735.963% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -4504.122% |
| BeyondSpring Inc. | 24.86 Million USD | -2932.717% |
| Synlogic, Inc. | 58.53 Million USD | -1188.329% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -4114.649% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -16687.289% |
| Peak Bio, Inc. | 1249.13 USD | -60368716.696% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1147.535% |
| Krystal Biotech, Inc. | 160.42 Million USD | -370.052% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -178.64% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -116.667% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -34864.21% |
| MannKind Corporation | 125.59 Million USD | -500.4% |
| Ikena Oncology, Inc. | 84.57 Million USD | -791.596% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -7716.782% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -741.603% |
| Gossamer Bio, Inc. | 183.75 Million USD | -310.366% |
| CohBar, Inc. | 12.38 Million USD | -5987.076% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1386.643% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -2633.975% |
| Legend Biotech Corporation | 583.14 Million USD | -29.313% |
| Mural Oncology plc | 192.07 Million USD | -292.607% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1023.036% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -4570.625% |
| Disc Medicine, Inc. | 91.12 Million USD | -727.528% |
| Champions Oncology, Inc. | 28.11 Million USD | -2582.622% |
| REGENXBIO Inc. | 321.15 Million USD | -134.803% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -13965.512% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1252.473% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1835.505% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -559.413% |
| Vaxart, Inc. | 90.72 Million USD | -731.167% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -8750.755% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1662.124% |
| Cellectis S.A. | 97.32 Million USD | -674.851% |
| Longeveron Inc. | 21.25 Million USD | -3448.635% |
| Repare Therapeutics Inc. | 167.35 Million USD | -350.585% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 44.586% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -896.874% |
| Revolution Medicines, Inc. | 498.76 Million USD | -51.19% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -11236.215% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1615.623% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -910.973% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -982.911% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -6718.128% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 84.208% |
| Denali Therapeutics Inc. | 527.23 Million USD | -43.028% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -8611.035% |
| Veru Inc. | 101.34 Million USD | -644.054% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3121.622% |
| Cingulate Inc. | 22.75 Million USD | -3213.321% |
| Passage Bio, Inc. | 108.38 Million USD | -595.721% |
| Context Therapeutics Inc. | 25.07 Million USD | -2907.604% |
| Exicure, Inc. | 14.07 Million USD | -5257.239% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -265.947% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1641.496% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -8116.859% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -198.668% |
| Nuvalent, Inc. | 149.49 Million USD | -404.432% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -9247.888% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -627.53% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -3415.712% |
| OmniAb, Inc. | 83.89 Million USD | -798.844% |
| Anew Medical, Inc. | 1.3 Million USD | -57869.037% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2201.566% |
| Lipocine Inc. | 15.08 Million USD | -4900.518% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1000.645% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -890.237% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1770.514% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -556.623% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -3268.857% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -13.542% |
| Ocugen, Inc. | 71.56 Million USD | -953.677% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -703.363% |
| Q32 Bio Inc. | 92.68 Million USD | -713.644% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -3461.372% |
| Alumis Inc. Common Stock | 158.17 Million USD | -376.744% |
| Equillium, Inc. | 50.6 Million USD | -1390.11% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1108.353% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -5322.905% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -3897.247% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1506.111% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -595.227% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -5984.9% |
| Dominari Holdings Inc. | 23.83 Million USD | -3063.772% |
| Edesa Biotech, Inc. | 9.22 Million USD | -8076.35% |
| vTv Therapeutics Inc. | 11.9 Million USD | -6233.123% |
| Bio-Techne Corporation | 563.03 Million USD | -33.931% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -84.46% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -180.584% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -470.08% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -5132.704% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -360.662% |
| Nkarta, Inc. | 131.65 Million USD | -472.795% |
| BioCardia, Inc. | 12.12 Million USD | -6121.31% |
| Iterum Therapeutics plc | 47.46 Million USD | -1488.618% |